How long it takes Lenvima takes to work depends on your cancer type, how far it has progressed, past treatments, and your current state of health. Many trials report on differences in progression-free survival or overall survival at the end of a set time frame, but analysis of various results, such as Kaplan-Meier Curves, reveal Lenvima appears to start working after 2 months, for cancers such as thyroid cancer, renal cell carcinoma, and endometrial carcinoma.

• Differences in progression-free survival (PFS) were noted at two months for 261 patients receiving Lenvima for thyroid cancer compared to 131 assigned placebo (total number 392). Lenvima-treated participants lived an average of 14.7 months longer than those taking placebo overall, with a PFS of 18.3 months reported compared to 3.6 months for those assigned placebo.
• For renal cell carcinoma, differences for PFS were noted at 2 months when Lenvima was used in conjunction with everolimus (L+E). Those receiving L+ E had a PFS of 14.6 months (with a range of 5.9 to 20.1 months) compared to 5.5 months (with a range of 3.5 to 7.1 months) for patients only receiving everolimus. The combination regimen resulted in a 63% reduction in the risk of disease progression or death compared with everolimus alone.
• For endometrial cancer, differences for PFS were noted at 2 months when Lenvima was used in conjunction with pembrolizumab with an overall response rate of 38.3% (ranging from 29% to 49%), a partial response rate of 27.7%, and a complete response rate of 10.6%. Sixty-nine percent of patients had a response lasting 6 months or longer.